Commenting on the agreement, Dr Simon Hirst, Sygnature’s Chief Executive Officer, said, “We are delighted that Heptares has chosen to collaborate with Sygnature on this programme.  Heptares’ decision to work with us demonstrates our growing reputation for delivering ‘top tier’ science coupled with high value and quality.”

Dr Miles Congreve, Head of Chemistry at Heptares said, "We are working with Sygnature on this drug discovery programme which forms a component of our efforts to develop novel GPCR-focused therapeutics.  Sygnature is becoming well-known and respected within the pharmaceutical industry for its high-quality medicinal and synthetic chemistry driven services.”